Fastograf 300 Injection is a specialized oncological supportive care medication containing 300 mcg of Filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF). It is designed to stimulate the bone marrow for increased neutrophil production, effectively reducing the risk of infections in patients undergoing chemotherapy, bone marrow transplantation, or suffering from severe chronic neutropenia. This product accelerates the recovery of neutrophil counts by binding to specific hematopoietic cell receptors, stimulating proliferation and differentiation of neutrophil precursors. Its administration via subcutaneous injection or intravenous infusion under medical supervision helps maintain chemotherapy schedule adherence by minimizing neutropenia duration and severity. Packaged in a 0.5 mL prefilled syringe or vial, Fastograf 300 must be stored refrigerated and protected from light. The drug is intended exclusively for hospital and oncology center use to ensure safe and effective treatment and requires continuous monitoring of patients' complete blood counts.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Filgrastim 300 mcg |
| Therapeutic Category | Oncology Supportive Care / Hematopoietic Growth Factor |
| Indications | Chemotherapy-induced neutropenia, Bone marrow transplantation, Severe chronic neutropenia, Mobilization of peripheral blood progenitor cells |
| Administration Route | Subcutaneous injection or Intravenous infusion |
| Packaging | Prefilled syringe or vial containing 300 mcg/0.5 mL |
| Storage Conditions | Refrigerate at 2°C – 8°C, do not freeze or shake, protect from light |
| Mechanism of Action | Stimulates proliferation and differentiation of neutrophil precursors by binding to hematopoietic cell surface receptors |
| Key Benefits | Reduces chemotherapy-induced neutropenia duration and severity, lowers infection risk, improves treatment continuity |
| Supervision | To be used under strict oncologist/hematologist supervision, with regular CBC monitoring |
| Manufacturer | Cytomed Therapeutics |
| Attributes | Description |
|---|---|
| Generic Name | Filgrastim |
| Dosage Strength | 300 mcg per 0.5 mL |
| Formulation | Injection |
| Intended Use | Support bone marrow recovery and neutrophil count increase |
| Side Effects | Bone pain, injection site reactions, mild fever |
| Shelf Life | As per manufacturer guidelines; store refrigerated |
| Handling Precautions | Avoid freezing and shaking, protect from direct light exposure |
| Route of Administration | Subcutaneous (SC) or Intravenous (IV) |
| Treatment Duration | Until desired neutrophil count is achieved, varies by patient condition |
| Monitoring Requirements | Complete blood counts (CBC) regularly during therapy |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
Fastograf 300 Injection offers a precisely measured 300 mcg dose in a 0.5 mL prefilled syringe or vial, ensuring accurate administration. Manufactured by Cytomed Therapeutics, it is specifically formulated for oncology supportive care with strict refrigeration and handling standards, providing reliable neutrophil recovery and infection risk reduction.
Yes, Fastograf 300 Injection is indicated for the mobilization of peripheral blood progenitor cells, facilitating their collection for transplantation purposes.
Fastograf 300 Injection must be stored refrigerated between 2°C to 8°C, must not be frozen or shaken, and should be protected from light to maintain its potency and safety.
Regular monitoring of complete blood counts (CBC) is essential during therapy with Fastograf 300 to track neutrophil levels and adjust treatment duration accordingly under oncologist supervision.
Fastograf 300 Injection is intended for hospital or oncology center use only, requiring administration under strict medical supervision due to its specialized dosage and monitoring requirements.
Country Of Origin: India
Product Name: Fastograf 300 Injection
Generic Name: Filgrastim 300 mcg
Manufacturer: Cytomed
Therapeutic Category: Oncology Supportive Care / Hematopoietic Growth Factor
Product Description:
Fastograf 300 Injection contains Filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF).
It is used to stimulate the bone marrow to produce more neutrophils (a type of white blood cell), helping reduce the risk of infection in patients receiving chemotherapy, bone marrow transplant, or suffering from neutropenia.
Indications:
• Chemotherapy-induced neutropenia
• Bone marrow transplantation
• Severe chronic neutropenia (SCN)
• Mobilization of peripheral blood progenitor cells (PBPC)
Mechanism of Action:
Filgrastim binds to specific cell surface receptors on hematopoietic cells, stimulating proliferation, differentiation, and activation of neutrophil precursors.
This leads to faster recovery of neutrophil counts and improved infection defense.
Dosage & Administration:
• Administered as subcutaneous (SC) injection or intravenous (IV) infusion.
• Dose depends on indication, body weight, and clinical condition.
• Treatment duration continues until the desired neutrophil count is achieved.
(To be given under oncologist/hematologist supervision.)
Key Benefits:
• Reduces duration and severity of chemotherapy-induced neutropenia.
• Lowers risk of life-threatening infections.
• Improves treatment continuity for cancer patients.
Packaging:
• Prefilled syringe / Vial containing 300 mcg/0.5 mL.
Storage:
• Store at 2°C – 8°C (Refrigerated).
• Do not freeze or shake.
• Protect from light.
Important Notes:
• For hospital/oncology use under strict medical supervision only.
• Side effects may include bone pain, injection site reactions, mild fever.
• Regular monitoring of complete blood counts (CBC) is essential during therapy.
Melizza Lifescience
Oncology supplier
Inclusive of all taxes
You Save: 0
Rajkot , India
Manufacturer, Professional Services, Distributor, Exporter, Importer, Wholesaler, Startup
GST- 24gqfpm5460r1z4
